Extended Data Fig. 8: Biosafety and biocompatibility evaluation of UltraHOF.
From: H-bonded organic frameworks as ultrasound-programmable delivery platform
a, The cell viability tests of HOF-TATB nanocrystals in human embryonic kidney 293 (HEK-293T) cells. Mean ± s.e.m.; at least three independent tests (n = 5). The hemolysis tests of HOF-TATB nanocrystals: photograph (b) and hemolysis statistical analysis (c); mean ± s.e.m.; at least three independent tests (n ≥ 3). d, In vivo biosafety evaluation by haematoxylin and eosin staining after sono-chemogenetics. Scale bar, 100 μm. n = 3 independent experiments for each sample. e, In vivo biocompatibility evaluation of the sono-chemogenetics by means of determining microglia (Iba1) activation. Statistical analysis of the Iba1 intensity. Mean ± s.e.m., n ≥ 3 mice in each group. Two-way ANOVA and Tukey’s multiple comparison tests. f, In vivo biocompatibility evaluation of the sono-chemogenetics by means of determining neuron apoptosis (caspase-3). Statistical analysis of the caspase-3 intensity. Mean ± s.e.m., n ≥ 3 mice in each group. Two-way ANOVA and Tukey’s multiple comparison tests. g, In vivo biocompatibility evaluation of the sono-chemogenetics by determining astrocytes (GFAP) activation. Mean ± s.e.m., n ≥ 3 mice in each group. Two-way ANOVA and Tukey’s multiple comparison tests. Statistical significance: P ≥ 0.05 (ns).
